Cancer immunotherapy
- Submission status
- Open
- Submission deadline
Recent advances in immunotherapy have transformed the treatment of some cancers. However, not all patients respond to these treatments. There is an unmet clinical need to develop new and improved immunotherapies and identify efficacious combinations, with an increasing number of immunotherapy drugs in development and clinical trials. There is also a need to identify reliable predictive biomarkers of response and resistance to immunotherapy.
With this Collection, a partnership between Nature Communications, Communications Medicine and Scientific Reports, we welcome submissions of primary research papers that focus on cancer immunotherapy. We aim to reiterate the interest of the journals in publishing high-quality clinical research in the field of cancer immunotherapy. We also remain interested in preclinical studies proposing new immunotherapy strategies and combinatorial approaches, as well as novel immune cell engineering, nanotechnology and bio-engineering developments applied to cancer immunotherapy.
We will highlight relevant papers in this Collection; unfortunately, we cannot guarantee that any individual paper will be included in the Collection.
Nature Communications is edited by in-house professional editors.
Communications Medicine is edited by both in-house professional editors and Editorial Board Members.
Scientific Reports is managed by in-house professional editors and edited by a team of Editorial Board Members.
Our editors work closely together to ensure the quality of our published papers and consistency in author experience.
